Related Experiment Video

Updated: Aug 15, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM

S De Vita, S De Matteis, L Laurenti

    Annals of Oncology : Official Journal of the European Society for Medical Oncology
    |November 3, 2005
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Related Experiment Videos

    Last Updated: Aug 15, 2026

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
    04:36

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

    Published on: October 17, 2025

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

    Articles linked to this work by shared authors, journal, and citation graph.

    Effect of silage from a new brachytic corn hybrid with a high harvest index on feeding behavior and performance of lactating dairy cows.

    Journal of dairy science·2025

    Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.

    European journal of haematology·2024

    Subjects with temporomandibular joint disc displacement and body posture assessment via rasterstereography: a pilot case-control study.

    European review for medical and pharmacological sciences·2020

    Pseudomixoma peritonei associated with appendiceal cistoadenoma rupture: case report.

    Il Giornale di chirurgia·2019

    Ability of HMGB1 protein to bind to intrinsically bent and non-bent DNA sites in the AMPD2 gene amplicon.

    Genetics and molecular research : GMR·2016

    Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2016

    Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Thymic Radiation is Associated with Worse Outcomes in Patients with NSCLC.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Bacillus Calmette-Guerin in controlling type 1 diabetes: A quasi-experimental randomized clinical trial.

    Caspian journal of internal medicine·2026

    Single-cell transcriptomic signatures of T cells associated with rituximab responsiveness in idiopathic nephrotic syndrome.

    iScience·2026

    Telemedicine-guided management of iodinated contrast media-associated anaphylaxis: A case report.

    Radiology case reports·2026

    Hybridoma-based generation of a functional IgM antibody targeting the 160-loop of influenza B virus haemagglutinin.

    Journal of immunological methods·2026

    Management of hyperthyroidism in pregnancy.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026

    Photodynamic activities of silicon (IV) phthalocyanines with different charges and their synergistic efficacy with immunotherapy.

    International immunopharmacology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us